NewsAvi Kapoor
Abbott Laboratories
ABT · NYSE
$102.45−$1.61 (−1.55%)TodayMarket closed ·
Prev close $104.06
Latest news
- NewsAvi Kapoor
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings
- Press releasePRNewswire
Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Press releasePRNewswire
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- Press releasePRNewswire
Abbott hosts conference call for third-quarter earnings
- Press releasePRNewswire
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
- Press releasePRNewswire
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
- News
3 Health Care Stocks With Whale Alerts In Today’s Session
- Press releasePRNewswire
Abbott declares 411th consecutive quarterly dividend
- Press releasePRNewswire
First Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care
- Press releasePRNewswire
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
- Press releasePRNewswire
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- Press releasePRNewswire
Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- Press releasePRNewswire
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- NewsVandana Singh
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
- Press releasePRNewswire
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- News
FDA Authorizes Abbott's Libre Duo, First Device To Continuously Monitor Both Glucose And Ketones
- NewsVandana Singh
Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation
- Press releasePRNewswire
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Press releasePRNewswire
Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- Press releaseBusiness Wire
First Bellwether Trial Today Against Reckitt Benckiser’s Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio
- NewsChris Katje
Congressman Ditches Blue Chip Stocks for Municipal Bonds: Here Are the Sales
- Press releasePRNewswire
Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Press releasePRNewswire
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- Press releaseGlobe Newswire
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- NewsAvi Kapoor
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results
- NewsLekha Gupta
Why Is Intuitive Surgical Stock Sinking Friday?
- NewsAvi Kapoor
Nasdaq Tumbles 1.5% Amid Selloff In Chip Stocks: Investor Sentiment Weakens, Greed Index Moves To ‘Fear’ Zone
- NewsVandana Singh
Abbott Brushes Off Procedure Volume Concerns, Lifts Outlook
- NewsPiero Cingari
Chip Selloff Drags Nasdaq 100, Gold Sinks Below $4,000: Stock Market Today
- NewsPiero Cingari
Abbott Stock's Best Day Ever: +13.6% On Earnings Beat, Guidance Raise
- News
Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript
- Press releasePRNewswire
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- NewsKaustubh Bagalkote
Netflix's Q3 Earnings Report Could Lead to $21.5 Billion Swing in Market Value
- News
'The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case' - WSJ
- Press releasePRNewswire
Abbott hosts conference call for second-quarter earnings
- Press releasePRNewswire
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
- Press releasePRNewswire
New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
- NewsPiero Cingari
The Hormuz Reopening Trade: These 20 Large-Cap Stocks Still Haven't Caught Up To Pre-War Levels
- Press releasePRNewswire
Abbott declares 410th consecutive quarterly dividend
- Press releasePRNewswire
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- News
MiniMed Announces Expanded Agreement With Abbott To Collaborate On Commercializing Dual Glucose-Ketone Sensors Designed To Integrate Exclusively With MiniMed Smart Dosing Systems
- NewsVandana Singh
Abbott's Strong AFib, Cardiac Device Data Fuels Heart-Rhythm Device Buzz
- Press releasePRNewswire
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
- Press releasePRNewswire
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
- Press releasePRNewswire
Abbott declares 409th consecutive quarterly dividend
- NewsAvi Kapoor
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
- NewsAvi Kapoor
Top 2 Health Care Stocks That May Crash In Q1
- Press releasePRNewswire
Abbott increases quarterly dividend for 54th consecutive year
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.